PL EN


Preferences help
enabled [disable] Abstract
Number of results
2009 | 56 | 3 | 423-431
Article title

New method for quantitative analysis of GD2 ganglioside in plasma of neuroblastoma patients

Content
Title variants
Languages of publication
EN
Abstracts
EN
Neuroblastoma, the most common extracranial solid tumour of childhood, is a malignancy of unknown origin and non-specific symptoms. One of the markers of the disease is GD2 ganglioside (disialoganglioside), which is abundantly expressed on the surface of neuroblastoma cells. Gangliosides are known to be shed by tumour cells and this phenomenon can be significant in cancer progression as they inhibit a number of immune responses both in vitro and in vivo. In search for novel markers useful in monitoring and prognosis of neuroblastoma, we developed and validated a new quantitative method of GD2 ganglioside analysis in human blood plasma. We evaluated the level of gangliosides in blood serum of 34 neuroblastoma patients using high-performance liquid chromatography. The technique was used to detect fluorescently labelled oligosaccharides derived from serum glycosphingolipids by enzymatic digestion with ceramide glycanase. The developed method allowed determination of GD2 concentrations at the picomole level and required only 40 µl of plasma, which should be particularly useful when the quantity of clinical material is limiting. Moreover, this method can be applied to study concentration of other gangliosides, as shown for GD3 ganglioside. Analysis of plasma samples from the 34 neuroblastoma patients did not reveal any correlations between the concentration of GD2 ganglioside and clinical parameters, including the results of therapy; it showed, however, that the concentration of GD2 ganglioside in the plasma of neuroblastoma patients decreased substantially in the course of treatment.
Publisher

Year
Volume
56
Issue
3
Pages
423-431
Physical description
Dates
published
2009
received
2009-04-07
revised
2009-07-13
accepted
2009-08-11
(unknown)
2009-08-31
Contributors
  • Laboratory of Molecular Genetics and Virology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland
  • Laboratory of Molecular Genetics and Virology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland
  • Laboratory of Molecular Genetics and Virology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland
  • Department of Paediatric Oncology and Haematology, University Children's Hospital, Collegium Medicum, Jagiellonian University, Kraków, Poland
  • Department of Paediatric Oncology and Haematology, University Children's Hospital, Collegium Medicum, Jagiellonian University, Kraków, Poland
  • Department of Paediatric Oncology and Haematology, University Children's Hospital, Collegium Medicum, Jagiellonian University, Kraków, Poland
author
  • Department of Analytical Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland
author
  • Laboratory of Molecular Genetics and Virology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland
References
  • Balwierz W (2004) Management strategy in neuroblastoma. Przegl Lek 61 (Suppl 2): 3-8 (in Polish).
  • Beiske K, Ambros PF, Burchill SA, Cheung IY, Swerts K (2005) Detecting minimal residual disease in neuroblastoma patients - the present state of the art. Cancer Lett 228: 229-240.
  • Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
  • Carubia JM, Yu RK, Macala LJ, Kirkwood JM, Varga JM (1984) Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Commun 120: 500-504.
  • Chang HR, Cordon-Cardo C, Houghton AN, Cheung NK, Brennan MF (1992) Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer 70: 633-638.
  • Chen S, Caragine T, Cheung NK, Tomlinson S (2000) Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones. Am J Pathol 156: 1085-1091.
  • d'Azzo A, Tessitore A, Sano R (2006) Gangliosides as apoptotic signals in ER stress response. Cell Death Differ 13: 404-414.
  • Evans AE, Baum E, Chard R (1981) Do infants with stage IV-S neuroblastoma need treatment? Arch Dis Child 56: 271-274.
  • Hakansson L, Fredman P, Svennerholm L (1985) Gangliosides in serum immune complexes from tumour-bearing patients. J Biochem 98: 843-849.
  • Hakomori S (2001) Tumor-associated carbohydrate antigens defining tumour malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 491: 369-402.
  • He X, Dagan A, Gatt S, Schuchman EH (2005) Simultaneous quantitative analysis of ceramide and sphingosine in mouse blood by naphthalene-2,3-dicarboxyaldehyde derivatization after hydrolysis with ceramidase. Anal Biochem 340: 113-122.
  • Hettmer S, Malott C, Woods W, Ladisch S, Kaucic K (2003) Biological stratification of human neuroblastoma by complex 'B' pathway ganglioside expression. Cancer Res 63: 7270-7276.
  • Hettmer S, McCarter R, Ladisch S, Kaucic K (2004) Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid. Br J Cancer 91: 389-397.
  • Hettmer S, Ladisch S, Kaucic K (2005) Low complex ganglioside expression characterizes human neuroblastoma cell lines. Cancer Lett 225: 141-149.
  • Kong Y, Li R, Ladisch S (1998) Natural forms of shed tumour gangliosides. Biochim Biophys Acta 1394: 43-56.
  • Ladisch S, Gillard B (1987) Isolation and purification of gangliosides from plasma. Methods Enzymol 138: 300-306.
  • Ladisch S, Wu ZL, Feig S, Ulsh L, Schwartz E, Floutsis G, Wiley F, Lenarsky C, Seeger R (1987) Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 39: 73-76.
  • Ladisch S, Li R, Olson E (1994) Ceramide structure predicts tumor ganglioside immunosuppressive activity. Proc Natl Acad Sci USA 91: 1974-1978.
  • Li R, Ladisch S (1991) Shedding of human neuroblastoma gangliosides. Biochim Biophys Acta 1083: 57-64.
  • Liour SS, Kapitonov D, Yu RK (2000) Expression of gangliosides in neuronal development of P19 embryonal carcinoma stem cells. J Neurosci Res 62: 363-373.
  • Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, Reisfeld RA (1989) Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 49: 2857-2861.
  • Neville DC, Coquard V, Priestman DA, te Vruchte DJ, Sillence DJ, Dwek RA, Platt FM, Butters TD (2004) Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling. Anal Biochem 331: 275-282.
  • Perez CA, Ravindranath MH, Soh D, Gonzales A, Ye W, Morton DL (2002) Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J 8: 384-394.
  • Ravindranath MH, Gonzales A, Soh D, Nishimoto K, Tam WY, Bilchik A, Morton DL, O'Day S (2001) Interleukin-2 binds to ganglioside GD(1b). Biochem Biophys Res Commun 283: 369-373.
  • Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ, Burchill SA (2004) A systematic review of molecular and biological tumour markers in neuroblastoma. Clin Cancer Res 10: 4-12.
  • Schumacher-Kuckelkorn R, Hero B, Ernestus K, Berthold F (2005) Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases. Pediatr Blood Cancer 45: 195-201.
  • Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP (1999) The international neuroblastoma pathology classification (the Shimada system). Cancer 86: 364-372.
  • Sietsma H, Nijhof W, Dontje B, Vellenga E, Kamps WA, Kok JW (1998) Inhibition of hemopoiesis in vitro by neuroblastoma-derived gangliosides. Cancer Res 58: 4840-4844.
  • Svennerholm L (1980) Ganglioside designation. Adv Exp Med Biol 125: 11.
  • Valentino LA, Ladisch S (1992) Localization of shed human tumour gangliosides: association with serum lipoproteins. Cancer Res 52: 810-814.
  • Valentino L, Moss T, Olson E, Wang HJ, Elashoff R, Ladisch S (1990) Shed tumor gangliosides and progression of human neuroblastoma. Blood 75: 1564-1567.
  • Varki A (1999) Glycosylation changes in cancer. In Essentials of Glycobiology. Varki A, Cummings R, eds. Cold Spring Harbor Laboratory Press, New York.
  • Weinstein JL, Katzenstein HM, Cohn SL (2003) Advances in the diagnosis and treatment of neuroblastoma. Oncologist 8: 278-292.
  • Wing DR, Garner B, Hunnam V, Reinkensmeier G, Andersson U, Harvey DJ, Dwek RA, Platt FM, Butters TD (2001) High-performance liquid chromatography analysis of ganglioside carbohydrates at the picomole level after ceramide glycanase digestion and fluorescent labeling with 2-aminobenzamide. Anal Biochem 298: 207-217.
  • Wu ZL, Schwartz E, Seeger R, Ladisch S (1986) Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 46: 440-443.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv56p423kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.